摘要
目的分析国内医院门诊患者的保肝药药物使用特征和药费情况,为合理用药提供参考。方法收集并统计2016年1月至2023年12月全国9个城市119家医疗机构的保肝药相关门诊处方数据,分析保肝药物的临床应用情况。结果本研究共调取3194167例患者的8635977张处方。门诊开具保肝药相关诊断最多的是乙型肝炎(7.59%)、肝硬化(5.11%)和非酒精性脂肪肝炎(4.53%),其中开具1~2种保肝药处方占比98.15%,口服剂型占比97.29%。近8年保肝药的药费总额从8537.91万元增长至10980万元,次均药费从85.15元增长至95.52元。甘草酸制剂是最常用的单药保肝方案,多烯磷脂酰胆碱+甘草酸制剂治疗是最常用的联合保肝方案。结论保肝药药费呈逐年上升趋势,给医保带来一定的负担,本研究对近8年全国肝病门诊保肝药用药情况进行分析,为未来开展保肝药物的综合评价提供基础数据支持。
OBJECTIVE To analyze the characteristics and drug cost of hepatoprotective drugs among outpatients in domestic hospitals and provide references for rational drug use.METHODS The outpatient prescription data of 119 hospitals in 9 cities from January 2016 to December 2023 was collected,and the clinical application of hepatoprotective drugs was analyzed.RESULTS A total of 8635977 prescriptions from 3194167 patients were obtained in this study.The most frequent diagnoses of hepatoprotective drugs were hepatitis B(7.59%),liver cirrhosis(5.11%)and non-alcoholic steatohepatitis(4.53%).98.15%of prescriptions for 1-2 hepatoprotective drugs are prescribed,and oral dosage forms account for 97.29%.The total drug cost of hepatoprotective drugs increased from 85.38 million yuan to 109.8 million yuan,and the average drug cost per time increased from 85.15 yuan to 95.52 yuan.The glycyrrhizin preparation was the most used regimen,and the polyene phosphatidylcholine+glycyrrhizin preparation was the most used regimen.CONCLUSIONS The aggregate costs on hepatoprotective medications appears a consistent annual increase,which brings economic burden to medical insurance.This study analyzes the trend of hepatoprotective drug costs in the past 8 years,which is of great significance to the drug management of patients with liver disease.
作者
武一
潘晨
姜静
程吟楚
赵莹
周效竹
刘冉佳
崔向丽
WU Yi;PAN Chen;JIANG Jing;CHEN Yinchu;ZHAO Ying;ZHOU Xiaozhu;LIU Ranjia;CUI Xiangli(Department of Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Reproductive Medical Center,PLA Rocket Force Characteristic Medical Center,Beijing 100086,China;Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2024年第17期1658-1664,共7页
Chinese Pharmaceutical Journal
基金
国家卫生健康委医院管理研究所医院药学高质量发展研究项目资助(NIHAYS2302)
北京药学会临床药学研究项目资助(LCYX-2022-16)。
关键词
乙型肝炎
保肝药
处方分析
药费
甘草酸制剂
hepatitis B
hepatoprotective drugs
prescription analysis
drug cost
glycyrrhizin preparation
